3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Carcinoma, Hepatocellular
5
Carcinoma, Renal Cell
4
Melanoma
2
Endometrial Neoplasms
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Hematologic Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Adenoid Cystic
1
Brain Neoplasms
1
Bone Neoplasms
1
Advanced Malignancies
1
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
1
Adenocarcinoma
1
Interventions
X-Rays
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Biopsy
4
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
tazemetostat
1
talazoparib
1
palbociclib
1
olaparib
1
irinotecan sucrosofate
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
LY3023414
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
lenvatinib
×
30 days
×
Clear all
No trials found.